UroViu Corporation has announced that its Uro-V single-use diagnostic cystoscopic system has received 510(k) clearance from the FDA. Additionally, the...
Medtronic plc announced the first patient enrolled in the Expand URO U.S. clinical trial for the Hugo robotic-assisted surgery (RAS) system
Molecular Partners was informed by Novartis that the company has requested Emergency Use Authorization (EUA) from the FDA for MP 0420 (ensovibep), a DARPin antiviral therapeutic candidate to treat COVID-19.
St Jude Medical has received CE Mark approval of its Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) for patients...
St. Jude Medical, Inc. announced CE Mark approval of the Quadra Allure MP cardiac resynchronization therapy pacemaker (CRT-P). The Quadra...
Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in CF patients.
St.Jude Medical has announced CE Mark approval for magnetic resonance (MR) conditional labeling for the company�s Quadra Allure MP cardiac...
Background and aims: The lack of valid therapeutic approach that can ameliorate the manifestations of NASH is a barrier to therapeutic development.
Molecular Partners announced that a planned futility analysis of MP 0420 (ensovibep) in the ongoing ACTIV-3 clinical study (NCT04501978) has not met the thresholds required to continue enrollment of adults with COVID-19 in the hospitalized setting.